Key Takeaways:
Catalyst Pharmaceuticals Inc. (Nasdaq: CPRX) reached a settlement with Hetero Labs Ltd. to resolve patent litigation, delaying the market entry of a generic version of its rare disease drug FIRDAPSE in the U.S. until January 2035.
The agreement resolves the lawsuit Catalyst and its licensor SERB S.A. brought against Hetero for its Abbreviated New Drug Application seeking to market a generic version of FIRDAPSE 10 mg tablets. "Pursuant to the terms of the Agreement, Hetero will not market its generic version of FIRDAPSE in the United States any earlier than a specified date in January 2035," the company said in a statement.
As part of the settlement, all ongoing patent litigation between the parties pending in the U.S. District Court for the District of New Jersey will be terminated. This avoids a trial that was scheduled to begin on May 18, 2026. The company previously settled similar ANDA litigation with Lupin Pharmaceuticals, Teva Pharmaceuticals, and Inventia Healthcare Limited.
The settlement removes a significant overhang for Catalyst by ending all pending patent challenges against FIRDAPSE, its primary revenue driver. The drug is approved for treating Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder. Securing market exclusivity until 2035 protects a revenue stream that reached $589.0 million in 2025 and is projected to grow to between $615 million and $645 million in 2026.
The resolution provides long-term clarity for investors, safeguarding FIRDAPSE's market position for nearly a decade longer than a potential negative trial outcome might have allowed. Investors will now focus on the company's execution of its commercial strategy and pipeline development, with the FIRDAPSE revenue stream secured. The settlement agreement will be submitted to the U.S. Federal Trade Commission and the U.S. Department of Justice for review, as required by law.
This article is for informational purposes only and does not constitute investment advice.
